⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198 | 1.00 | — | — | |
| Fluoride SCHEMBL27461973 | 1.00 | — | — | |
| SCHEMBL969300 | 1.00 | — | — | |
| SCHEMBL4621927 | 1.00 | FABP6 (0.35) | — | |
| Ammonia Solution, Strong SCHEMBL4693667 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL2080171 | 0.97 | — | — | |
| SCHEMBL7117843 | 0.97 | — | — | |
| SCHEMBL7117839 | 0.97 | — | — | |
| SCHEMBL6678827 | 0.97 | — | — | |
| SCHEMBL935971 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | claimed |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | claimed |
| US-20240174684-A1 | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS | BELLBROOK LABS, LLC | 2024-05-30 | — | — | US | claimed |
| WO-2024101336-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 国立大学法人京都大学 | 2024-05-16 | — | — | WO | claimed |
| EP-4368625-A1 | SHP2 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-05-15 | — | — | EP | claimed |
| CN-117916242-A | SHP2 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-4291188-A1 | INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENTS | Bellbrook Labs, Llc (US) | 2023-12-20 | — | — | EP | claimed |
| CN-116997339-A | Inhibitors of cGAS activity as therapeutic agents | 贝尔布鲁克实验室有限责任公司 | 2023-11-03 | — | — | CN | claimed |
| US-20230339930-A1 | Antiviral Heteroaryl Ketone Derivatives | PFIZER INC. (US) | 2023-10-26 | — | — | US | claimed |
| CN-111542516-B | IRAK4 inhibitors and uses thereof | 新标立亚医疗有限公司 | 2023-07-18 | — | — | CN | claimed |
| WO-2001007433-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-02-01 | — | — | WO | claimed |
| WO-2000078748-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-12-28 | — | — | WO | claimed |
| WO-2000043383-A1 | PIPERIDINYLQUINOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-07-27 | — | — | WO | claimed |
| EP-0929519-A1 | $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-21 | — | — | EP | claimed |
| US-5847153-A | β-sulfonyl hydroxamic acids | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-08 | — | — | US | claimed |
| WO-1998013340-A1 | β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-02 | — | — | WO | claimed |
| EP-0430847-A1 | Procedure for the preparation of N-cyclopropyl-4-fluoroanilines | CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) | 1991-06-05 | — | — | EP | claimed |
| EP-0175363-B1 | 4,5-DIHYDRO-3(2H)-PYRIDAZINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE | CASSELLA Aktiengesellschaft (DE) | 1990-01-17 | — | — | EP | claimed |
| US-4816454-A | CARDIOVASCULAR DISORDERS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1989-03-28 | — | — | US | claimed |
| EP-0175363-A2 | 4,5-Dihydro-3(2H)-pyridazinones, process for their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1986-03-26 | — | — | EP | claimed |